Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolpidem for Parkinson's Disease
NCT01351168Phase 2Withdrawn
- Sponsor
- Rush University Medical Center
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zolpidem sublingual tablet in Parkinson's disease (PD) (4 arms), sponsored by Rush University Medical Center. Primary endpoint: Unified Parkinson's Disease Rating Scale. Status: withdrawn.
02
Drugs
zolpidem sublingual tablet
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01351168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01351168.